サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1635875

点頭てんかん（ウエスト症候群）治療市場：治療クラス別、薬剤タイプ別、調剤別、投与経路別、流通チャネル別、エンドユーザー別、地域別、2025-2033年

Infantile Spasms Therapeutics Market by Therapeutic Class, Drug Type (Vigabatrin, Adrenocorticotropic Hormone, and Others ), Dosage, Route of Administration, Distribution Channel, End User, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 128 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
点頭てんかん（ウエスト症候群）治療市場：治療クラス別、薬剤タイプ別、調剤別、投与経路別、流通チャネル別、エンドユーザー別、地域別、2025-2033年
出版日: 2025年01月10日
発行: IMARC
ページ情報: 英文 128 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

点頭てんかん（ウエスト症候群）治療市場の世界市場規模は2024年に38億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに52億米ドルに達し、2025～2033年の成長率（CAGR）は3.52％になると予測しています。乳幼児のけいれん発作の有病率の上昇、大衆の健康意識の高まりによる早期診断、製品承認数の増加と強力なパイプライン医薬品の存在が、市場を牽引する主な要因のいくつかです。

点頭てんかん（ウエスト症候群）治療とは、通常生後4ヵ月から1歳の幼児におけるけいれん発作やてんかん症候群の治療に用いられる治療法を指します。痙攣のエピソードは、突然体が硬直し、腕、脚、頭が前屈みになり、背中が弓なりになり、短く微妙な発作を起こすことが特徴です。小児けいれんは、脳腫瘍、出生時の損傷、脳の感染症、遺伝的変化によって引き起こされることがあります。乳児けいれんには、ステロイド、コルチコトロピン注射ゲルやグルココルチコイドによるホルモン療法、抗けいれん薬など、多くの治療法があります。点頭てんかん（ウエスト症候群）治療は、けいれん発生後3週間以内に実施することで持続的な効果が得られやすく、治療には単剤療法と併用療法があります。小児けいれんは、身体診察、神経学的診察、脳のMRI、血液検査、尿検査などで診断されます。

点頭てんかん（ウエスト症候群）治療市場傾向：

新生児における小児けいれんの有病率の増加は、市場の成長を促す重要な要因です。これは、世界中で出生率が大幅に上昇していることに起因しています。これに伴い、製品承認数の増加や強力なパイプライン医薬品の存在が市場にプラスの影響を与えています。発作を検知して介護者に警告を発する発作警告装置の導入など、小児けいれんの治療における継続的な技術進歩が市場に弾みをつけています。また、早期診断と治療に関する認識が広まったことが、小児けいれん治療薬の普及率を高め、市場の成長を後押ししています。しかし、治療成功率の低さ、治療費の高さ、医薬品承認のための厳しい規制、未診断患者の増加など、さまざまな要因が点頭てんかん（ウエスト症候群）治療市場の成長を阻害しています。それとは反対に、この病状に関する認識を促進するために、いくつかの国の政府や民間団体によって実施されている好意的な取り組みやプログラムが、市場の前向きな見通しを生み出しています。さらに、主要企業が成功率の高い革新的な医薬品の開発に重点を置いた広範な研究開発（R&D）活動を展開していることも、市場を牽引しています。市場に寄与するその他の要因としては、医療費の拡大、共同研究・提携・合併買収（M&A）の増加、急速な都市化、可処分所得水準の上昇などが挙げられます。

本レポートで扱う主な質問

  • 世界の点頭てんかん（ウエスト症候群）治療市場の市場規模は？
  • 2025-2033年における世界の点頭てんかん（ウエスト症候群）治療市場の予想成長率は？
  • 世界の点頭てんかん（ウエスト症候群）治療市場を牽引する主要因は何か？
  • 世界の点頭てんかん（ウエスト症候群）治療市場に対するCOVID-19の影響は？
  • 世界の点頭てんかん（ウエスト症候群）治療市場の治療クラス別内訳は？
  • 薬剤タイプに基づく点頭てんかん（ウエスト症候群）治療市場の世界の内訳は？
  • 調剤に基づく世界の点頭てんかん（ウエスト症候群）治療市場の内訳は？
  • 世界の点頭てんかん（ウエスト症候群）治療市場の投与経路別の内訳は？
  • 世界の点頭てんかん（ウエスト症候群）治療市場の流通チャネル別の内訳は？
  • 点頭てんかん（ウエスト症候群）治療市場の世界におけるエンドユーザー別の内訳は？
  • 世界の点頭てんかん（ウエスト症候群）治療市場における主要地域は？
  • 世界の点頭てんかん（ウエスト症候群）治療市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の点頭てんかん（ウエスト症候群）治療市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：治療クラス別

  • 抗けいれん薬
    • 市場動向
    • 市場予測
  • コルチコステロイド
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：薬剤タイプ別

  • ビガバトリン
    • 市場動向
    • 市場予測
  • 副腎皮質刺激ホルモン
    • 市場動向
    • 市場予測
  • その他（フェーズIII）
    • 市場動向
    • 市場予測

第8章 市場内訳：調剤別

  • 固体
    • 市場動向
    • 市場予測
  • 液体
    • 市場動向
    • 市場予測

第9章 市場内訳：投与経路別

  • 経口
    • 市場動向
    • 市場予測
  • 非経口
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第10章 市場内訳：流通チャネル別

  • 病院薬局
    • 市場動向
    • 市場予測
  • 小売薬局
    • 市場動向
    • 市場予測
  • オンライン薬局
    • 市場動向
    • 市場予測

第11章 市場内訳：エンドユーザー別

  • 病院
    • 市場動向
    • 市場予測
  • クリニック
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第12章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ

第13章 促進要因・抑制要因・機会

  • 概要
  • 促進要因
  • 抑制要因
  • 機会

第14章 バリューチェーン分析

第15章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第16章 価格分析

第17章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • H. Lundbeck A/S
    • Mallinckrodt plc
    • ORPHELIA Pharma
    • Teva Pharmaceuticals USA Inc.（Teva Pharmaceutical Industries Ltd.）
図表

List of Figures

  • Figure 1: Global: Infantile Spasms Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019-2024
  • Figure 3: Global: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 4: Global: Infantile Spasms Therapeutics Market: Breakup by Therapeutic Class (in %), 2024
  • Figure 5: Global: Infantile Spasms Therapeutics Market: Breakup by Drug Type (in %), 2024
  • Figure 6: Global: Infantile Spasms Therapeutics Market: Breakup by Dosage (in %), 2024
  • Figure 7: Global: Infantile Spasms Therapeutics Market: Breakup by Route of Administration (in %), 2024
  • Figure 8: Global: Infantile Spasms Therapeutics Market: Breakup by Distribution Channel (in %), 2024
  • Figure 9: Global: Infantile Spasms Therapeutics Market: Breakup by End User (in %), 2024
  • Figure 10: Global: Infantile Spasms Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 11: Global: Infantile Spasms Therapeutics (Anticonvulsants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Infantile Spasms Therapeutics (Anticonvulsants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Infantile Spasms Therapeutics (Corticosteroids) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Infantile Spasms Therapeutics (Corticosteroids) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Infantile Spasms Therapeutics (Other Therapeutic Classes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Infantile Spasms Therapeutics (Other Therapeutic Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Infantile Spasms Therapeutics (Vigabatrin) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Infantile Spasms Therapeutics (Vigabatrin) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Infantile Spasms Therapeutics (Adrenocorticotropic Hormone) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Infantile Spasms Therapeutics (Adrenocorticotropic Hormone) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Infantile Spasms Therapeutics (Other Drug Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Infantile Spasms Therapeutics (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Infantile Spasms Therapeutics (Solid) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Infantile Spasms Therapeutics (Solid) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Infantile Spasms Therapeutics (Liquid) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Infantile Spasms Therapeutics (Liquid) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Infantile Spasms Therapeutics (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Infantile Spasms Therapeutics (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Infantile Spasms Therapeutics (Parenteral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Infantile Spasms Therapeutics (Parenteral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Infantile Spasms Therapeutics (Other Routes of Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Infantile Spasms Therapeutics (Other Routes of Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Infantile Spasms Therapeutics (Hospital Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Infantile Spasms Therapeutics (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Infantile Spasms Therapeutics (Retail Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Infantile Spasms Therapeutics (Retail Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Infantile Spasms Therapeutics (Online Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Infantile Spasms Therapeutics (Online Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Infantile Spasms Therapeutics (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Infantile Spasms Therapeutics (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Global: Infantile Spasms Therapeutics (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Global: Infantile Spasms Therapeutics (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Global: Infantile Spasms Therapeutics (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Global: Infantile Spasms Therapeutics (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: North America: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: North America: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: United States: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: United States: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Canada: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Canada: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Asia-Pacific: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Asia-Pacific: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: China: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: China: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Japan: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Japan: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: India: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: India: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: South Korea: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: South Korea: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Australia: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Australia: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Indonesia: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Indonesia: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Others: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Others: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Europe: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Europe: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Germany: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Germany: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: France: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: France: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: United Kingdom: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: United Kingdom: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Italy: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Italy: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Spain: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Spain: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Russia: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Russia: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Others: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Others: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Latin America: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Latin America: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Brazil: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Brazil: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Mexico: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Mexico: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Others: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 90: Others: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 91: Middle East and Africa: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 92: Middle East and Africa: Infantile Spasms Therapeutics Market: Breakup by Country (in %), 2024
  • Figure 93: Middle East and Africa: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 94: Global: Infantile Spasms Therapeutics Industry: Drivers, Restraints, and Opportunities
  • Figure 95: Global: Infantile Spasms Therapeutics Industry: Value Chain Analysis
  • Figure 96: Global: Infantile Spasms Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Infantile Spasms Therapeutics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Infantile Spasms Therapeutics Market Forecast: Breakup by Therapeutic Class (in Million USD), 2025-2033
  • Table 3: Global: Infantile Spasms Therapeutics Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 4: Global: Infantile Spasms Therapeutics Market Forecast: Breakup by Dosage (in Million USD), 2025-2033
  • Table 5: Global: Infantile Spasms Therapeutics Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 6: Global: Infantile Spasms Therapeutics Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 7: Global: Infantile Spasms Therapeutics Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 8: Global: Infantile Spasms Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 9: Global: Infantile Spasms Therapeutics Market: Competitive Structure
  • Table 10: Global: Infantile Spasms Therapeutics Market: Key Players
目次
Product Code: SR112025A6789

The global infantile spasms therapeutics market size reached USD 3.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.2 Billion by 2033, exhibiting a growth rate (CAGR) of 3.52% during 2025-2033. The rising prevalence of seizures in infants, increasing health consciousness among the masses resulting in early diagnosis, and the growing number of product approvals and presence of strong pipelines drugs represent some of the key factors driving the market.

Infantile spasms therapeutics refer to the treatment procedures used for treating seizures or an epilepsy syndrome in young children, usually aged between four months and a year of age. An episode of spasm is characterized by the body stiffening suddenly, arms, legs, and head bending forward, the back arching, and short, subtle seizures. Infantile spasm can be caused by brain tumors, birth injuries, infection of the brain, and genetic changes. There are a number of therapeutic options that are available for infantile spams, including steroids, hormone therapy with corticotropin injection gel and glucocorticoids, as well as antiseizure medications. Infantile spasms therapeutics are more likely to provide sustained results if they are implemented within three weeks after the spasms occur, and treatment can be done by monotherapy or combination therapy. Infantile spasms are diagnosed by physical examination, neurological examination, MRI of the brain, and blood and urine examinations.

Infantile Spasms Therapeutics Market Trends:

The increasing prevalence of infantile spasms among newborn babies is a significant factor driving the growth of the market. This can be attributed to a considerable rise in the birth rates across the globe. In line with this, the growing number of product approvals and presence of strong pipelines drugs are impacting the market positively. Continual technological advancements in the treatment of infantile spasms, such as the introduction of seizure alert device for detecting seizures and alerting the caregivers, are providing an impetus to the market. Also, the widespread awareness regarding early diagnosis and treatment is enhancing the penetration rate of infantile spasm drugs, thereby fueling the market growth. However, various factors, such as lesser treatment success rates, high cost of treatment, strict regulations for drug approval, and the augmenting undiagnosed patient pool, are impeding the growth of the infantile spasms therapeutics market. On the contrary, favorable initiatives and programs conducted by the government and private organizations of several countries for promoting awareness regarding the medical condition is creating a positive market outlook. The market is further driven by the extensive research and development (R&D) activities conducted by the key market players focusing on the development of innovative drugs with higher success rates. Some of the other factors contributing to the market include the expanding healthcare expenditure, rising number of collaborations, partnerships and merger and acquisitions (M&As), rapid urbanization, and inflating disposable income levels.

Key Market Segmentation:

Therapeutic Class Insights:

  • Anticonvulsants
  • Corticosteroids
  • Others

Drug Type Insights:

  • Vigabatrin
  • Adrenocorticotropic Hormone
  • Others (Phase III)

Dosage Insights:

  • Solid
  • Liquid

Route of Administration Insights:

  • Oral
  • Parenteral
  • Others

Distribution Channel Insights:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

End User Insights:

  • Hospitals
  • Clinics
  • Others

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for infantile spasms therapeutics. Some of the factors driving the North America infantile spasms therapeutics market include the presence of several key players, inflating disposable income levels, and the widespread awareness regarding early disease diagnosis and prevention.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global infantile spasms therapeutics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include H. Lundbeck A/S, Mallinckrodt plc, ORPHELIA Pharma, Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1. How big is the global infantile spasms therapeutics market?
  • 2. What is the expected growth rate of the global infantile spasms therapeutics market during 2025-2033?
  • 3. What are the key factors driving the global infantile spasms therapeutics market?
  • 4. What has been the impact of COVID-19 on the global infantile spasms therapeutics market?
  • 5. What is the breakup of the global infantile spasms therapeutics market based on the therapeutic class?
  • 6. What is the breakup of the global infantile spasms therapeutics market based on the drug type?
  • 7. What is the breakup of the global infantile spasms therapeutics market based on the dosage?
  • 8. What is the breakup of the global infantile spasms therapeutics market based on route of administration?
  • 9. What is the breakup of the global infantile spasms therapeutics market based on the distribution channel?
  • 10. What is the breakup of the global infantile spasms therapeutics market based on the end user?
  • 11. What are the key regions in the global infantile spasms therapeutics market?
  • 12. Who are the key players/companies in the global infantile spasms therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Infantile Spasms Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapeutic Class

  • 6.1 Anticonvulsants
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Corticosteroids
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Vigabatrin
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Adrenocorticotropic Hormone
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others (Phase III)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Dosage

  • 8.1 Solid
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Liquid
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Oral
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Parenteral
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacy
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Retail Pharmacy
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Pharmacy
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast

11 Market Breakup by End User

  • 11.1 Hospitals
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Clinics
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast
  • 11.3 Others
    • 11.3.1 Market Trends
    • 11.3.2 Market Forecast

12 Market Breakup by Region

  • 12.1 North America
    • 12.1.1 United States
      • 12.1.1.1 Market Trends
      • 12.1.1.2 Market Forecast
    • 12.1.2 Canada
      • 12.1.2.1 Market Trends
      • 12.1.2.2 Market Forecast
  • 12.2 Asia-Pacific
    • 12.2.1 China
      • 12.2.1.1 Market Trends
      • 12.2.1.2 Market Forecast
    • 12.2.2 Japan
      • 12.2.2.1 Market Trends
      • 12.2.2.2 Market Forecast
    • 12.2.3 India
      • 12.2.3.1 Market Trends
      • 12.2.3.2 Market Forecast
    • 12.2.4 South Korea
      • 12.2.4.1 Market Trends
      • 12.2.4.2 Market Forecast
    • 12.2.5 Australia
      • 12.2.5.1 Market Trends
      • 12.2.5.2 Market Forecast
    • 12.2.6 Indonesia
      • 12.2.6.1 Market Trends
      • 12.2.6.2 Market Forecast
    • 12.2.7 Others
      • 12.2.7.1 Market Trends
      • 12.2.7.2 Market Forecast
  • 12.3 Europe
    • 12.3.1 Germany
      • 12.3.1.1 Market Trends
      • 12.3.1.2 Market Forecast
    • 12.3.2 France
      • 12.3.2.1 Market Trends
      • 12.3.2.2 Market Forecast
    • 12.3.3 United Kingdom
      • 12.3.3.1 Market Trends
      • 12.3.3.2 Market Forecast
    • 12.3.4 Italy
      • 12.3.4.1 Market Trends
      • 12.3.4.2 Market Forecast
    • 12.3.5 Spain
      • 12.3.5.1 Market Trends
      • 12.3.5.2 Market Forecast
    • 12.3.6 Russia
      • 12.3.6.1 Market Trends
      • 12.3.6.2 Market Forecast
    • 12.3.7 Others
      • 12.3.7.1 Market Trends
      • 12.3.7.2 Market Forecast
  • 12.4 Latin America
    • 12.4.1 Brazil
      • 12.4.1.1 Market Trends
      • 12.4.1.2 Market Forecast
    • 12.4.2 Mexico
      • 12.4.2.1 Market Trends
      • 12.4.2.2 Market Forecast
    • 12.4.3 Others
      • 12.4.3.1 Market Trends
      • 12.4.3.2 Market Forecast
  • 12.5 Middle East and Africa
    • 12.5.1 Market Trends
    • 12.5.2 Market Breakup by Country
    • 12.5.3 Market Forecast

13 Drivers, Restraints, and Opportunities

  • 13.1 Overview
  • 13.2 Drivers
  • 13.3 Restraints
  • 13.4 Opportunities

14 Value Chain Analysis

15 Porters Five Forces Analysis

  • 15.1 Overview
  • 15.2 Bargaining Power of Buyers
  • 15.3 Bargaining Power of Suppliers
  • 15.4 Degree of Competition
  • 15.5 Threat of New Entrants
  • 15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

  • 17.1 Market Structure
  • 17.2 Key Players
  • 17.3 Profiles of Key Players
    • 17.3.1 H. Lundbeck A/S
      • 17.3.1.1 Company Overview
      • 17.3.1.2 Product Portfolio
      • 17.3.1.3 Financials
      • 17.3.1.4 SWOT Analysis
    • 17.3.2 Mallinckrodt plc
      • 17.3.2.1 Company Overview
      • 17.3.2.2 Product Portfolio
      • 17.3.2.3 Financials
    • 17.3.3 ORPHELIA Pharma
      • 17.3.3.1 Company Overview
      • 17.3.3.2 Product Portfolio
    • 17.3.4 Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.)
      • 17.3.4.1 Company Overview
      • 17.3.4.2 Product Portfolio

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.